Baxter International (BAX) vs Glaukos (GKOS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Glaukos (GKOS) has outperformed Baxter International (BAX) over the past year, gaining 104.8% versus a gain of 4.7%. Over five years, GKOS leads with a +284.2% price change compared with -69.9% for BAX. Baxter International is the larger company by market cap ($12.39 billion vs $10.16 billion), about 1.2 times the size, while Glaukos is growing revenue faster (+32.3% vs +5.7%).
On valuation, Baxter International trades at a lower forward P/E (11.8x vs 328.9x for Glaukos). Baxter International pays a dividend yielding 0.83%, while Glaukos does not currently pay one. Baxter International converts more of its revenue into profit, with a net margin of -8.5% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BAX | GKOS |
|---|---|---|
| Share price | $23.97 | $172.18 |
| Market cap | $12.39B | $10.16B |
| 1-day change | -1.60% | +6.55% |
| YTD return | +25.43% | +52.49% |
| 1-year return | +4.67% | +104.76% |
| 5-year return | -69.92% | +284.16% |
| Forward P/E | 11.75 | 328.86 |
| EPS (TTM) | $-1.85 | $-3.26 |
| Dividend yield | 0.83% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $11.24B | $507.44M |
| Revenue growth (YoY) | +5.72% | +32.33% |
| Net income (latest FY) | $-957.00M | $-187.69M |
| Gross margin | 30.05% | 55.72% |
| Operating margin | -2.74% | -39.33% |
| Net margin | -8.51% | -36.99% |
| 52-week high | $30.00 | $191.62 |
| 52-week low | $15.73 | $73.16 |
| Distance from 52-week high | -20.10% | -10.15% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +16.48% | +15.40% |
| Average volume | 6.63M | 791.91K |
| Shares outstanding | 517.00M | 58.98M |
| Employees | 37,500 | 1,094 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GKOS has outperformed BAX by 100.1 percentage points over the past year.
- Baxter International is more profitable, keeping -8.5 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
- Glaukos grew revenue faster in its latest fiscal year (+32.33% vs +5.72%).
About Baxter International
BAX stock →Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Health Care · Medical/Dental Instruments · 37,500 employees
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
BAX vs GKOS FAQ
Which is bigger, Baxter International or Glaukos?
Baxter International (BAX) is larger, with a market capitalization of $12.39B compared with $10.16B for Glaukos (GKOS).
Which stock has performed better over the past year, BAX or GKOS?
GKOS returned +104.76% over the past 12 months, compared with +4.67% for BAX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Baxter International or Glaukos?
Baxter International pays a dividend yielding 0.83%, while Glaukos does not currently pay a regular dividend.
Are Baxter International and Glaukos in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.